These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 17476171)

  • 1. Bisphosphonates. A cornerstone of osteoporosis treatment.
    Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
    [No Abstract]   [Full Text] [Related]  

  • 2. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
    Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
    J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
    [No Abstract]   [Full Text] [Related]  

  • 3. Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
    Yamaguchi K; Oizumi T; Funayama H; Kawamura H; Sugawara S; Endo Y
    J Oral Maxillofac Surg; 2010 Apr; 68(4):889-97. PubMed ID: 20056305
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw: new developments in an old disease.
    Khan A
    J Rheumatol; 2008 Apr; 35(4):547-9. PubMed ID: 18398947
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
    Barrier A; Lescaille G; Rigolet A; Descroix V; Goudot P; Ruhin B
    Rev Stomatol Chir Maxillofac; 2010 Sep; 111(4):196-202. PubMed ID: 20810140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
    Bilezikian JP
    Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisphosphonates for osteoporosis].
    Narusawa K; Nakamura T
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():311-5. PubMed ID: 18161123
    [No Abstract]   [Full Text] [Related]  

  • 12. [Osteoporosis treatment: choices and options].
    Reginster JY
    Pol Arch Med Wewn; 2007 Jul; 117(7):283-4. PubMed ID: 17966592
    [No Abstract]   [Full Text] [Related]  

  • 13. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 14. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
    Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
    Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. By the way, doctor. I'm 60 and have osteoporosis. My doctor is recommending Fosamax, but I'm concerned about jawbone problems. Are there any other drugs I can take?
    Robb-Nicholson C
    Harv Womens Health Watch; 2006 Dec; 14(4):8. PubMed ID: 17299880
    [No Abstract]   [Full Text] [Related]  

  • 16. Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
    Gopal GK; Tam KL; Krishnan SP; Maddern IL
    N Z Med J; 2014 Feb; 127(1389):81-5. PubMed ID: 24548959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML; Leonard M; Licata AA
    Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture prevention in postmenopausal women.
    Mosekilde L; Vestergaard P; Langdahl B
    Clin Evid; 2006 Jun; (15):1543-60. PubMed ID: 16973058
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteochemonecrosis of jaws and bisphosphonates.
    Khosa AD; Nayyar MS; Beirne JC
    Ir Med J; 2007 Mar; 100(3):410-1. PubMed ID: 17491545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual mid-shaft fractures during long-term bisphosphonate therapy.
    Odvina CV; Levy S; Rao S; Zerwekh JE; Rao DS
    Clin Endocrinol (Oxf); 2010 Feb; 72(2):161-8. PubMed ID: 19302584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.